SimBioSys, Inc.

SimBioSys is a pioneering, VC-backed TechBio startup at the forefront of digital precision medicine, leveraging advanced AI and computational modeling to revolutionize cancer treatment with spatial biophysics. Through our SaaS-based TumorSight™ platform, SimBioSys delivers actionable insights for individualized care, empowering clinicians with predictive tools and enhanced decision-making capabilities.

•	National Strategy & Business Development: In charge of national strategy and business development initiatives within the breast oncology continuum of care, focusing on Surgical Oncology, Diagnostic Radiology and Medical Oncology.
•	Go-To-Market Leadership: Responsible for the go-to-market strategy and marketing execution for the TumorSight suite of applications.
•	KOL Relationship Management: Accountable for cultivating and managing relationships with Key Opinion Leaders, developing strategies to position TumorSight as a leader in oncology solutions.
•	PACS and Middleware Expertise: Skilled in integrating TumorSight with hospital PACS and middleware systems to streamline imaging workflows and support clinical decision-making.
•	HCP & Clinical Strategy: Drive the development and execution of targeted messaging for healthcare professionals, ensuring alignment with the latest oncology care advancements.
•	Market Segmentation & Targeting: Conduct in-depth market segmentation to identify and target key healthcare professionals, ensuring impactful and tailored engagement strategies.
•	Digital Marketing & Campaigns: Spearhead email campaigns and oversee social media strategy to enhance brand visibility and increase product adoption among healthcare professionals.

Director of Marketing and Customer Success

Restfully

Restfully is a pioneering behavioral health platform and consumer application dedicated to addressing pediatric sleep disorders. By integrating evidence-based practices with user-friendly technology, Restfully empowers parents and clinicians to achieve remarkable improvements in children's sleep health. 

•	Innovative Platform Development: Pioneered the development of a cutting-edge behavioral health platform and consumer application, specifically targeting the treatment of pediatric sleep disorders. Successfully achieved a 94% resolution rate, positively impacting the lives of thousands of children.
•	Secured Seed Financing: Raised $750K in seed funding to propel the initiative, driving the platform’s growth and expansion into the healthcare market.
•	Cross-Functional Team Leadership: Formed and expertly led a diverse team of 14 entrepreneurs, 8 behavioral health clinicians, and 3 Key Opinion Leaders, ensuring alignment and collaboration across all facets of the project.
•	Business Growth & IP Licensing: Strategically directed business growth initiatives and orchestrated the licensing of intellectual property to employee benefits partners, expanding the platform's reach and impact in the healthcare industry.

CEO & Co-Founder

Boston Scientific

Boston Scientific’s Interventional Oncology division, following the BTG acquisition, specializes in minimally invasive intra-arterial therapies, including TheraSphere (Y-90) radioembolization and LC Bead embolization for liver cancer treatment, as well as the Visual Ice percutaneous cryoablation system for the treatment of kidney and lung cancers

•	Strategic Leadership & Business Development: Led national strategy and market development initiatives for BSC's interventional oncology suite of intra-arterial embolization therapies, including TheraSphere & LC Beads for the treatment of liver cancer.
•	Clinical Specialty Messaging: Developed targeted messaging for downstream clinical specialties within the oncology continuum of care, encompassing Interventional Radiology, Surgical Oncology, Medical Oncology, Radiation Oncology, Transplant Surgery, and Hepatology. 
•	KOL Management & Strategy: Managed relationships with Key Opinion Leaders (KOLs) and devised strategies to leverage their influence in advancing the company's oncology objectives. 
•	Technical Innovation: Identified and implemented technical innovation projects within the Interventional Oncology business unit, driving forward-thinking solutions and enhancing clinical outcomes.

Senior Product Manager

•	Achieved Highest Honors: Million Dollar Club FY16 
•       Finished #4: in FY16 company stack rankings  
•       Finished #1: FY16 LUMI sales rankings
•       Responsible for the sale and marketing of BTG's suite of Interventional Oncology products for the treatment of Hepatocellular Carcinoma. 
•	TheraSphere® is a powerful*, well-tolerated liver cancer therapy that consists of millions of small glass microspheres containing radioactive yttrium-90. The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood flow.
•	LC Bead® is a controlled embolization system intended for the purpose of embolizing the blood vessels of a variety of hypervascularized tumors and arteriovenous malformation.
•	Work closely with Interventional Radiology, Surgical Oncology, Transplant Oncology, Radiation Oncology, Nuclear Medicine, Medical Oncology and Hepatology.
•	Administrative Call Points - C-Suite CEO, CFO & COO
•	Extensive experience in Special Procedures and Cath Lab
•	Extensive experience managing the IRB process for HDE’s and Radioactive Materials Licensing

Senior Sales Representative

Agendia

•	Achieved Highest Honors - Presidents Club Qualifier - FY-2013 
•	Developed a corporate wide partnership with 21st Genesis Care (the largest privately held medical group in the country)
•	Co-managed corporate relationship with Florida Cancer Specialist (700+ Physician Medical Oncology Group)
•	Spearheaded corporate partnership with CBL Path (National Pathology Laboratory)
•	Managed relationships with KOL’s on the East Coast 
•	Responsible for the sale of Agendia’s Symphony Suite of Genomic Profiling and Molecular Sub-Typing tests for breast and colon cancer
•	Call points include Surgical Oncology, Medical Oncology, Radiology and Radiation Oncology
•	Devised a prudent sales strategy that incorporates each medical specialties involvement in the continuum of cancer treatment decision making and planning

Hologic, Inc.

•	Achieved Highest Honors – President's Club Qualifier for sales in 2008 
•	Finished #4 of 51 nationally in company stack rankings for fiscal year 2008	
•	Finished #5 of 42 nationally in company stack rankings for biopsy sales in 2009  
•	Worked in tandem with the Surgical Oncology and Radiation Oncology communities to implement a standard of care changing method of delivering Radiation Therapy for the treatment of Breast Cancer 
•	Trained and assisted Surgical Oncologists, General & Breast Surgeons in the Operating Room to professionally advise the specific surgical techniques for the ideal placement of the MammoSite Radiation Therapy Catheter
•	Provided clinical/technical support to Radiation Oncology & Physics Team in the treatment planning stages of radiation therapy (well trained in treatment planning software manufactured by Varian-BrachyVision and Nucletron-Oncentra)
•	Responsible for selling ATEC breast biopsy system (Capital/Disposable) to hospitals and surgical practices (well trained in both Ultrasound & Stereotactic imaging modalities)
•	Responsible for selling the Trident Specimen Radiograph to Hospitals (100K piece of imaging/capital equipment) for margin assessment in the Operating Room and calcification imaging in the Stereotactic Suite

Stryker

• Achieved highest honors – Two time President Circle Qualifier for 2005 and 2006
• Awarded Rookie of the Year honors in 2005
• Attained 181% of sales quota in 2005 and 170% of sales quota in 2006
• Finished #5 of 58 in 2006 Company Stack Rankings and #6 of 54 in overall 2005 rankings
• Sold and Implemented a wide variety of Interventional Patient Care products 
• Established and maintained strategic relationships at the corporate level at various NYC based IDN’s (NY- Presbyterian, NYCHHC, GNYHA, St. Vincent’s Catholic Health System)

Senior Medical Sales Representative

With over 20 years of experience advancing the healthcare ecosystem, I bring a proven track record across sales, marketing, customer success, and strategic leadership roles. My focus is on driving innovation in med-tech, molecular diagnostics, radiopharmaceuticals, AI-powered platforms, and minimally invasive or targeted therapies that transform care for high-impact disease states.

I thrive at the intersection of emerging technologies and commercial execution—aligning market access, clinical strategy, and customer adoption to accelerate growth and improve patient outcomes. Passionate about building teams, launching novel technologies, and scaling commercial impact across oncology, radiology, interventional procedures, and precision medicine.

Taplio

Vince Loughlin's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Vince Loughlin's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Vince Loughlin's Linkedin Analytics